Examining the efficacy, safety, and patient acceptability of the etonogestrel implantable contraceptive by Hohmann, Heather
© 2009 Hohmann, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Patient Preference and Adherence 2009:3 205–211
Patient Preference and Adherence
205
r e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Examining the efficacy, safety, and patient 
acceptability of the etonogestrel implantable 
contraceptive
Correspondence: Heather Hohmann 
University of Pittsburgh School of  
Medicine, Department of Obstetrics,  
Gynecology, and reproductive Sciences,  
Magee-womens Hospital, 300 Halket  
Street, Pittsburgh, PA 15213, USA 
Tel +1 412 641 1441 
Fax +1 412 641 1133 
email hhohmann@mail.magee.edu
Abstract: Contraceptive implants provide long-acting, highly effective reversible contraception. 
The etonogestrel implant (ENG implant) is a single rod implant that offers three years of efficacy. 
The ENG implant was designed to provide contraceptive efficacy by inhibiting ovulation 
and Pearl Index scores reported for this method are similar to other long-acting reversible 
contraception as well as similar to sterilization. The implant has been shown to be safe during 
breast feeding and may improve symptoms of dysmenorrhea and endometriosis. Irregular 
bleeding patterns can be expected with the device’s use and should be addressed in order to 
decrease rates of discontinuation.
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Introduction
Subdermal contraceptive implants have been studied and used in humans for over 
twenty years.1 Contraceptive implants provide long-acting, highly effective reversible 
contraception. The most recently introduced subdermal implant, Implanon® (N.V. Organon, 
Oss, the Netherlands), also referred to as the etonogestrel (ENG) implant, is a single rod 
implant that offers three years of contraceptive efficacy.2 The ENG implant has been 
used in more than 30 countries, including Australia, Indonesia, and the Netherlands, 
and was approved by the United States Food and Drug Administration (FDA) in 2006. 
The ENG implant is an excellent option for women with contraindications to estrogen 
in addition to any woman who desires long-acting reversible contraception.
The ENG implant is a single rod implant measuring 4 cm long and 2 mm in 
diameter with a solid core of ethylene vinyl acetate (EVA) impregnated with 68 mg of 
etonogestrel, the biologically active metabolite of desogestrel.3,4 The EVA copolymer 
allows controlled release of hormone over three years of use.5 Each implant is provided 
in a disposable sterile inserter for subdermal application.
Mechanism of action
The ENG implant was designed to provide contraceptive efficacy by inhibiting 
ovulation.4 Researchers have evaluated for evidence of ovulation in subjects with the 
ENG implant using both progesterone concentrations and ultrasound. In a study of 
32 women, weighing between 80% and 120% of ideal body weight, randomized to 
receive either Implanon®, between day 1 and 5 of menses, or Norplant System® (Wyeth, 
Madison, NJ, USA), between day 1 and 7 of menses, progesterone levels were noted to 
be above the threshold for ovulation for the first time in two subjects at 30 months in the 
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ENG implant users and at 12 months in one Norplant System® 
user.6 Ovulation was confirmed by ultrasound in both subjects 
at 30 months in the ENG group. In the Norplant System® group 
ovulation was not confirmed by ultrasound until 18 months 
of use. Although this study was designed to have subjects 
complete 36 months of observation, only seven women in 
the ENG implant group and three women in the Norplant 
System® group completed the full time course. Additionally, 
both groups of subjects had estradiol levels decrease to early 
follicular range after implant insertion. During treatment no 
subjects had continuously low or high estradiol levels.6
Davies and colleagues7 demonstrated a similar effect 
on ovulation suppression during one year of follow up of 
15 women. Subjects with a mean age of 32 had a partially 
leached ENG implant, assuring a hormone release rate 
of 40 µg/day, inserted between day one and five of their 
menstrual cycle. During the study period, no luteal activity was 
demonstrated utilizing serum hormone levels or ultrasound. 
In support of the ENG implants ability to suppress ovulation, 
this study also demonstrated that the cervical mucous assess-
ment six weeks following implant insertion was significant 
thickened based on a mean Insler value that had fallen 
significantly from 13, pre-insertion, to 3.5 (p = 0.0001).7
Pharmacology
Serum levels of ENG above 90 pg/ml have been shown to be 
adequate to prevent ovulation.8 Eight hours after insertion, 
ENG serum levels rise to a mean concentration of 265.9 ± 
80.9 pg/mL, with maximum serum concentrations seen by 
day 4 after insertion, with a variation from day 1 to day 13.6 
After one year of use the serum concentration decreases to a 
mean of 196 pg/mL6,9,10 and decreased after three years of use 
to a mean of 156 pg/mL.3,4 Serum levels become undetectable 
at less than 20 pg/mL one week after removal. Ovulation will 
occur in the majority of women within six weeks of ENG 
implant removal.6
After insertion of the ENG implant, estradiol (E2) levels 
initially decrease to early follicular-phase range.9 Following 
this initial decrease, E2 levels will gradual rise. Given the ENG 
implants’ ability to suppress ovulation, it appears that the phar-
macology of the ENG implant creates a situation of anovulation 
with normal endogenous E2 synthesis. One study of 70 subjects 
demonstrated that there was not a significant difference 
between baseline and end-of-study estrogen levels.11
Efficacy
Multiple large trials have demonstrated the high efficacy of 
the ENG implant. A recently published integrated analysis 
of 11 international clinical trials with a total of 923 subjects 
revealed that no pregnancies were reported while the ENG 
implant was in place.12 Six pregnancies occurred with a 
conception date occurring within the first two weeks after 
implant removal, yielding a Pearl Index score of 0.27, 
0.30, and 0.38 per 100 women years of use through years 
one, two, and three, respectively.12 These results support 
prior published data that found zero pregnancies among 
1,716 women who used the implant between two and five 
years (Pearl Index 0.0 [95% confidence interval 0.00, 0.09]).9 
The Pearl Index scores reported for the ENG implant are 
similar to other long-acting reversible contraception as well 
as similar to sterilization. The limitation on this data is that 
efficacy information is not available for women with weights 
that are above 130% of ideal weight. The quick return to 
fertility seen in the ENG users in the integrated analysis may 
be explained by the pharmacologic data that demonstrates 
E2 levels during ENG implant use to be in the range of the 
follicular phase. This E2 level suggests that follicles are 
present during implant use and thus ovulation can occur 
rapidly after removal.5,12
A multicenter Mexican study followed 417 women dur-
ing three years of ENG implant use.1 A total of 256 women 
(61.4%) completed the full three years of use. Women 
enrolled in this study had a mean weight of 59.4 ± 9.3 kg 
and a mean body mass index (BMI) of 24.9 ± 3.9, with 
19.4% of subjects categorized as overweight (BMI  25) 
and 8.9% categorized as obese (BMI  30). Once again, no 
pregnancies were recorded in this study which corresponded 
to 958.5 women years of observation.
A randomized Chinese study of 200 women directly 
compared the ENG implant to the six-capsule levonorgestrel 
(LNG) implant for a four-year period.13 Of 153 women who 
completed the full trial, no pregnancies were reported in 
either group. This data further supports the ENG implant’s 
effectiveness and suggests that further research may 
demonstrate that the device has acceptable efficacy for greater 
than three years of use.
Controlled clinical trials are able to give information 
about efficacy with perfect use, but information about 
typical use failure rates is essential for patient counseling. 
Three years of post-marketing data from Australia demon-
strated 218 confirmed pregnancies during ENG implant use 
when this method was newly introduced to the country.14 
This data set gives a failure rate of 1.07 per 1000 insertions. 
Of the cases reported, 21% of patients were found to have 
been pregnant prior to the time of implant insertion and 
39% of failures were due to “noninsertion.” Although the Patient Preference and Adherence 2009:3 207
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study reports that some physician recognized the failure of 
insertion, the series did not include the number of providers 
who failed to make this observation. In total, 21% of cases 
had insufficient data to detect the reason for failure and 
the remaining 19% of pregnancies were due to method 
failure. Of the 43 women who experienced a contraceptive 
failure, eight were determined to be secondary to interactions 
with other medications, carbamazepine being the most 
notable. Although no specific studies have examined the 
ENG implant’s interactions with hepatic enzyme-inducing 
medications, the package insert instructs women to use an 
additional contraceptive method for at least seven days 
after stopping such drugs. Until further research is done 
in this particular area, the post-marketing data suggests 
that the ENG implant should not be considered first-line 
contraception for women chronically on these types of 
medications. Additionally, one failure was in a woman who 
reported weight gain of greater than 10 kg between the time 
of insertion and the pregnancy, thus highlighting the fact 
that there is limited data about ENG implant efficacy in 
overweight and obese women.
Results of the above studies demonstrate the ENG 
implant’s excellent efficacy. Even when accounting for the 
failures noted in the Australian post-marketing surveillance, 
the implant continues to have one of the highest efficacies 
of any method available.
Insertion and removal
The ENG implant is inserted with a pre-loaded single use, 
sterile applicator. Knowledge and training of the proper 
insertion and removal techniques are essential for clinical 
efficacy and for the prevention of complications. The implant 
is typically inserted in the nondominant arm 6 to 8 cm above 
the elbow. At completion of the insertion proper placement 
of the implant should be done by palpating the patient’s 
arm.15 Most studies report insertion times averaging two 
minutes or less.15
Overall, low numbers of ENG implant site complications 
are reported in the literature. In a large multicenter trial, 
Croxatto and colleagues2 reported a 1.3% complication rate. 
Examples cited by the author were having a visible implant 
tip after insertion and blood loss from the injection site. 
Additionally, an American study reported a 2.5% rate of 
reported intermittent pain at the insertion site over a two-year 
period of use.16
Timing of insertion is dependant on the patient’s prior 
use of contraception. Additionally, a negative pregnancy 
test should be documented on all patients undergoing ENG 
implant insertion. For women without preceding hormone 
use, the ENG implant should be inserted within five days 
of the start of menses. When switching from a combined 
oral contraceptive, insertion should occur within seven 
days of the last active pill. Patients switching from another 
progestin-only method can have the implant placed at 
anytime while on the progestin-only pill, at the time of 
intra-uterine device (IUD) or implant removal, or on the 
due date of the next contraception injection. Implants may 
be inserted within five days of a first trimester abortion, 
within six weeks of a second trimester abortion, or within 
six weeks of childbirth.3
The package labeling indicates that the ENG implant 
needs to be removed at the end of three years of use.3 If the 
implant is unable to be palpated by the clinician prior to 
removal, imaging techniques may be necessary prior to 
proceeding. Case reports have utilized high frequency 
(10 MHz) ultrasound to detect the acoustic shadow associated 
with the implant17 as well as magnetic resonance imaging 
as a second line modality if needed.18 Once the implant has 
been located, a 2–3 mm incision is made vertically over the 
implant under sterile conditions. The rod is than removed 
utilizing the “pop-out” technique previously described for 
Norplant System® removal.19 Funk and colleagues16 published 
an average removal time of 3.5 min (range, 0.2–60 min) 
and reported difficulties in only two of 330 removals. This 
included an implant that broke during removal necessitating 
a second attempt for complete removal. In a large multicenter 
study, removal difficulties were reported in 3% of cases.2 
The most common reason for difficulty was secondary to 
implants being placed too deep.
Counseling
Given the number of contraceptive options available, it is 
essential that providers focus their efforts on helping women 
chose the best contraceptive method and providing coun-
seling that helps improve continuation rates of the chosen 
method. When discussing long-term reversible contraception, 
physicians are obligated to present all suitable options to their 
patients and review indications and contraindications for 
each of the methods. Contraindications to the ENG implant 
listed on the package insert include known or suspected 
pregnancy, active venous thromboembolic disease, active 
liver disease, undiagnosed genital tract bleeding, known or 
suspected breast cancer, progesterone dependant tumors, 
or allergy to any of the implants components.3 As mentioned 
above, women chronically using hepatic enzyme-inducing 
medications may not be good candidates for this method of Patient Preference and Adherence 2009:3 208
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contraception. Patients who are good candidates for this form 
of contraception are those that desire long-term reversible 
birth control, have no contraindications to ENG implant use, 
accept implant insertion and removal, and are ready to accept 
a change in menstrual bleeding patterns.
Safety and side effect profile
Bleeding patterns
A change in bleeding patterns is common and expected from 
continuous progestin-only contraceptives. An integrated 
analysis of 11 international trials which took place in the US, 
Chile, Asia, and Europe analyzed safety data from a total of 
942 subjects. Of subjects included in the analysis of bleed-
ing patterns, 65% completed the study in which they were 
enrolled and 35% of subjects discontinued their study par-
ticipation early.12 Overall 11.1% of subjects discontinued the 
ENG implant for bleeding irregularities. As a group, subjects 
experienced 17.5 days of bleeding and spotting per 90-day 
reference period. Infrequent bleeding was seen in 33.3% of 
reference periods, amenorrhea made up 21.4% of reference 
periods, prolonged bleeding made up 16.9% of reference 
periods, and frequent bleeding was reported in 6.1% of all 
reference periods. Overall the greatest number of bleeding 
days was seen in the first 90 days of placement and decreased 
between reference periods 2 and 3, remaining stable from that 
time point. Unfortunately, although bleeding patterns were 
similar between the studies no consistent bleeding pattern 
could be demonstrated for any individual woman.
A retrospective Swiss study was performed at 12 centers 
in order to assess acceptability and side-effect profile of the 
ENG implant.20 A total of 1183 women had the ENG implant 
inserted, of which 991 (84%) completed one follow-up 
visit. Mean time from insertion to first follow-up visit was 
224 days. Normal bleeding patterns were reported by only 
11% of women. Infrequent bleeding was seen in 28% of 
women, where as prolonged bleeding was reported in 15% 
of women and metromenorrhagia was reported in 16% of 
women. Of women with one follow-up visit, 23.7% had the 
implant removed prematurely. The most frequently reported 
adverse event leading to removal was prolonged and frequent 
bleeding, comprising 45% of removals for side effects.
In order to reduce the probability of method discontinu-
ation, different regimes have been examined with the goal 
of improving bleeding profiles.21–23 There is currently only 
one study that has examined the use of oral medications to 
reduce the amount and duration and bleeding in ENG implant 
users.22 This study randomized 179 women into one of four 
treatments. Subjects were women who had used the implant 
for greater than three months and experienced prolonged or 
frequent bleeding. Treatments were mifepristone 25 mg taken 
twice on day 1 followed by four days of placebo, mifepristone 
25 mg twice on day 1 followed by four days ethinyl estradiol 
(EE) 20 µg in the morning and placebo at night, doxycycline 
100 mg twice a day for five days, or placebo twice a day 
for five days. Mifepristone combined with EE and doxy-
cycline both significantly reduced bleeding episodes (mean 
4.3 days [95% CI 3.5–5.3] and 4.8 days [95% CI 3.9–5.8], 
respectively).22 Despite the results of this study, the limited 
availability of mifepristone in the US decreases the utility 
of this study’s results. Doxycycline may be considered as a 
method to decrease bleeding episodes in ENG implant users, 
keeping in mind the risk of side effects.
Dysmenorrhea and endometriosis
Evidence suggests that dysmenorrhea may be improved in 
ENG implant users.16,24 Simarily, new preliminary data sug-
gests that the therapeutic effect of the ENG implant is simi-
lar to depot medroxyprogesterone acetate (DMPA) for the 
treatment of symptomatic endometriosis.25 An American trial 
demonstrated that among women with a history of dysmen-
orrhea at baseline, 81% showed improvement with implant 
use.16 Out of the total subject population, 48% reported 
decreased dysmenorrhea with ENG implant use while only 
8% showed an increase in the condition. Similarly, Croxatto24 
reported a 35% incidence of dysmenorrhea amongst subjects 
at baseline with 82% of these women reporting improvement 
in symptoms at the end of the study. When complying data 
from multiple ENG implant studies, differences in bleeding 
pattern during ENG implant use was not correlated to 
reported incidence or severity of dysmenorrhea.26
A recent open, prospective, randomized pilot study 
conducted as a noninferiority trial demonstrated that the 
ENG implant was not worse than DMPA for treatment of 
histologically proven symptomatic endometriosis.25 Using 
visual analog scale measurements of pain, a 68% decrease 
in pain score was seen in the ENG implant group and a 53% 
decrease in pain score was seen in the DMPA group after six 
months of use. Study withdraw rates were similar for each 
group (four of 21 in the ENG implant group, seven of 20 in 
the DMPA group). Half of the subjects who withdrew from 
the ENG implant group reported unbearable bleeding-spotting 
episodes. The other two subjects withdrew for therapy-
resistant dysmenorhrea and hot flashes, respectively. Reasons 
for withdrawal in the DMPA group included hot flashes, pelvic 
pain resistant to treatment, weight gain, desire to conceive, 
severe depression, and loss of hair. Overall, of women who Patient Preference and Adherence 2009:3 209
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completed the trial, 57% of the ENG implant group reported 
being satisfied or very satisfied with their treatment.
weight changes
Weight changes attributed to the use of the ENG implant 
have been described in a number of clinical trials, although 
the percentage of women who ultimately have the implant 
removed for this reason is low. Based on results of a large 
American trial of the implant over a two-year period, weight 
increase was reported in about 12% of subjects,16 but only 
3.3% of women withdrew because of this weight increase. 
The mean increase in BMI from baseline to last measurement 
was 0.7 kg/m2. Croxatto and colleagues2 reported that approx-
imately 20% of women reported a greater than 10% increase 
in BMI over baseline at one or more measurements. The mean 
increase in BMI over the study’s three-year time period was 
3.5%, but the mean change in BMI was only 0.8kg/m2, similar 
to the results from the American trial. Zheng and colleagues13 
reported a change in body weight in 100 Chinese women 
using the ENG implant with a breakdown of 0.82 kg, 1.15 kg, 
2.5 kg, and 3.1 kg for years 1, 2, 3, and 4 of use. Importantly, 
no women withdrew from the study secondary to weight gain. 
In a retrospective Swiss study of implant users, 9% of 991 
women at first visit (mean time of 224 days since implant 
insertion, range 1–677 days) and 9% of 306 women at the 
second visit (mean time of 347 days since implant insertion, 
range 15–709 days) reported weight gain during implant use, 
but only 7% of women requesting implant removal reported 
the primary reason as weight gain.20 Lastly, in a retrospective 
British study following ENG implant use in 324 women, 
of the 277 for whom information was available, 14 (5%) 
women who discontinued implant use within one year cited 
weight change as their primary reason.27 Thus, the overall 
removal rates because of weight change appear to be in the 
3%–7% range in non-Asian populations.
Acne
In a three year study of 635 women, acne was the second 
most common (12.6%) nonbleeding adverse event associated 
with ENG implant use.24 This result is consistent with results 
from the integrated analysis of international clinical trials 
in which 11.8% of drug-related adverse events were from 
acne.12 An American trial of 315 subjects provided baseline 
and post-ENG implant acne information.16 Approximately 
26% of women had acne at baseline and 24% of women had 
acne after treatment. From the total population, 16% reported 
a decrease from baseline, 70% reported no change, and 14% 
reported increased acne. Of subjects with baseline acne, 61% 
reported decreased acne post-treatment and only 7% reported 
an increase in acne post-treatment. For those women without 
acne at baseline, 84% reported no change and 16% reported 
increase in this skin condition.
The results related to acne make it difficult to offer 
patients clear expectations regarding the incidence or severity 
of acne while using the ENG implant. Patients should 
be counseled that there is no apparent trend in regards to 
acne incidence or improvement while using this method of 
contraception.
Breast feeding
The ENG implant appears to be safe to use in breastfeeding 
women. An open-label nonrandomized comparison study 
of breastfeeding women using either the ENG implant or 
a copper IUD for contraception followed 80 women/infant 
pairs for four months.28 Forty-two women chose to use the 
ENG implant with the remaining 38 women choosing the 
copper IUD. All women were between ages 18 and 40 and 
were between 28 and 56 days postpartum at the start of the 
trial. Overall, no significant difference in total fat, protein, 
or lactose content of the breast milk was found between the 
two groups. Importantly, 24-hour milk production and infant 
growth rates were not different between the two groups. 
Infants were exposed to the etonogestrel with an initial dose 
of 19.86 ng/kg/day, equivalent to 1.7% of the maternal dose, 
during the first month of use, but this dose decreased between 
months 2 and 4.28 After completion of this trial, researchers 
followed women and infants over a three-year period to 
evaluate any differences in long term outcomes.29 Over 80% 
of subjects in each group completed this follow up. During 
this time, there was no difference between the two group’s 
infant growth rates or biparietal head circumferences. Even 
though the original study was not powered for this outcome, 
the results further support the initial conclusion of ENG 
implant safety for breastfeeding women.
Bone mineral density
Progestin-only hormonal contraception’s influence on bone 
mineral density (BMD) has become an area of controversy 
since the FDA required the inclusion of a black box warning 
on the package insert for DMPA. Beerthuizen and colleagues30 
reported on a comparative study of BMD in users of the ENG 
implant versus users of nonhormonal IUDs. Forty-four ENG 
users and 29 IUD users, age 18–40 years, were followed for 
two years. BMD was measured through the use of dual energy 
X-ray absortiometry (DEXA) at the lumbar spine, proximal 
femur, and distal radius. Estradiol levels were comparable Patient Preference and Adherence 2009:3 210
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between the groups at baseline and showed no correlation 
to baseline BMD. No clinically significant difference was 
seen in BMD between the ENG implant users and the IUD 
users. No relationship was noted between estradiol levels 
and changes in BMD in this study.
A longitudinal three-year trial comparing BMD of the 
forearm of women using either the ENG implant or the LNG 
implant found no difference between groups.31 At 36 months, 
both groups had significant decreases in BMD at the distal 
radius, −5.9% in the ENG implant group and −4.4% in the 
LNG implant group, but no difference in the ultradistal 
radius, where trabecular bone predominates. Although a 
decrease in BMD was seen in this study, it is important to 
consider that the BMD in the forearm is not the best predictor 
of future fracture. Further, there is no long term data that 
shows that this result has any clinical significance.
Effect on lipid profile and liver function
In order to evaluate the ENG implants affect on lipid 
profile, Biswas and colleagues32 conducted a randomized 
trial comparing the ENG implant and the Norplant System® 
following 80 subjects over two years.32 Only three ENG 
implant users discontinued prior to the study’s completion. 
This study demonstrated that ENG implant users had a 
significant decrease in serum total cholesterol (TC), high-
density lipoprotein (HDL) cholesterol, and low-density 
lipoprotein (LDL) cholesterol, which was similar to Norplant 
System® users. A similar decrease in total cholesterol in 
21% of subjects was noted in an American trial of the ENG 
implant,16 but unlike the results from Biswas and colleagues,32 
this trial also reported a decrease in triglycerides in 33% of 
women using the ENG implant. No significant change in the 
HDL/TC ratio was reported by Biswas and colleagues32 but a 
significant decrease in the HDL/LDL ratio for ENG implant 
users was seen at one year with a return to pre-insertion 
level at two years. Despite these results, the change in HDL 
was only 5.8% lower at two years compared to baseline and 
the HDL/LDL ratio was never within a range associated 
with increase risk of cardiovascular disease. The authors 
concluded that ENG implant use should not significantly 
increase the risk of cardiovascular disease.
A case-control study of 18 women followed for 12 weeks 
after ENG implant placement demonstrated that these sub-
jects had a significant decrease in C-reactive protein, HDL, 
LDL, cholesterol, testosterone, and sex-binding hormone 
globulin.33 These results lead the authors to conclude that use 
of this method of contraception does not increase cardiac risk 
factors in young healthy women. Importantly, manufacturers 
of the implant recommend following cholesterol values in 
women with known elevated lipid profiles throughout the 
use of the implant.3
Biswas and colleagues34 reported the effects of the ENG 
implant on liver function tests using the same study design as 
described above. The authors reported a significant increase 
in mean total and unconjugated bilirubin in both Norplant 
System® and ENG implant users. Despite this increase, 
levels never exceeded the normal range. The researchers did 
notice an initial significant increase in aspartate transami-
nase levels in ENG implant users at six months, but after a 
year of use levels declined toward baseline. Contrary to the 
above trials, Funk and colleagues16 reported no significant 
change in liver function parameters over a two-year use of 
the ENG implant. Additionally, Inal and colleagues11 found 
no significant difference between baseline and end-of-study 
serum glutamic oxalate transaminase, serum glutamic 
pyruvic transaminase, fasting glucose, HDL, cholesterol, 
or triglycerides. The mixed results suggest that there may be 
a small amount of liver dysfunction in ENG implant users. 
The clinical significance of this in healthy women is unclear. 
But these changes could have consequences in women with 
known liver dysfunction.
Conclusion
The ENG implant provides women with an additional highly 
effective nonuser-dependant reversible contraceptive option. 
With greater contraceptive options available, we as providers 
may be better able to match women’s contraceptive needs and 
desires with an appropriate method. The primary advantage of 
the ENG implant over other types of contraception is the low 
rate of contraceptive failure in women who have the implant 
inserted. The trade-off for women is irregularly irregular 
bleeding that occurs throughout the lifespan of use. Given the 
high efficacy of this method, we need to find ways to minimize 
bleeding issues in order to improve continuation rates. 
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